Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003413 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00003413 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 32 participants.
The verdict
NCT00003413, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating patients with stage III or stage IV ovarian epithelial cancer.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- DRUG melphalan
- DRUG carmustine
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 1998-09 |
| Est. Completion | 2001-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003413
The ClinicalTrials.gov registry entry for NCT00003413 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00003413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003413 about?
NCT00003413 is a clinical study titled "Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II...
What is the current status of trial NCT00003413?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 1998-09. Estimated completion is 2001-02.
What interventions are being tested in trial NCT00003413?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), melphalan (DRUG), carmustine (DRUG), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003413?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.